Insider Unloading: MYRON WENTZ Sells $179K Worth Of Usana Health Sciences Shares

On June 12, a recent SEC filing unveiled that MYRON WENTZ, 10% Owner at Usana Health Sciences USNA made an insider sell.

What Happened: WENTZ's recent move involves selling 3,700 shares of Usana Health Sciences. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The total value is $179,857.

Tracking the Wednesday's morning session, Usana Health Sciences shares are trading at $47.16, showing a down of 0.0%.

Delving into Usana Health Sciences's Background

Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.

A Deep Dive into Usana Health Sciences's Financials

Revenue Challenges: Usana Health Sciences's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -8.28%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.

Key Profitability Indicators:

• Gross Margin: The company maintains a high gross margin of 81.09%, indicating strong cost management and profitability compared to its peers.

• Earnings per Share (EPS): Usana Health Sciences's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 0.86.

Debt Management: Usana Health Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.

Assessing Valuation Metrics:

• Price to Earnings (P/E) Ratio: The P/E ratio of 14.69 is lower than the industry average, implying a discounted valuation for Usana Health Sciences's stock.

• Price to Sales (P/S) Ratio: The current P/S ratio of 1.01 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): The company's EV/EBITDA ratio 4.7 is below the industry average, indicating that it may be relatively undervalued compared to peers.

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Why Insider Transactions Are Key in Investment Decisions

Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.

Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.

Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.

But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.

Exploring Key Transaction Codes

For investors, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Usana Health Sciences's Insider Trades.

This article was generated by Benzinga's automated content engine and reviewed by an editor.